Art. -Nr.: HY-12214A

NVP-2

41 Cited Publications

Kundenbewertung

Based on 41 publication(s) in Google Scholar

NVP-2 is a potent and selective ATP-competitive cyclin dependent kinase 9 (CDK9) probe, inhibits CDK9/CycT activity with an IC₅₀ of 0.514 nM. NVP-2 displays inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases with IC₅₀ values of 0.584 μM, 0.706 μM, and 0.605 μM, respectively. NVP-2 induces cell apoptosis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.05%
CAS. Nr.: 1263373-43-8
Formel: C₂₇H₃₇ClN₆O₂
Molecular Weight:513.07

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

NVP-2 Chemical Structure

CAS. Nr.: 1263373-43-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (41)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

CDK9

0.5 nM (IC₅₀)

Alle CDK Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	5.78 μM Compound: NVP-2; 5	Antiproliferative activity against human A549 cells incubated for 72 hrs by celltiter-glo luminescent assay Antiproliferative activity against human A549 cells incubated for 72 hrs by celltiter-glo luminescent assay	[PMID: 39178382]
CESS	IC₅₀	0.01 μM Compound: NVP-2; 5	Antiproliferative activity against human CESS cells incubated for 72 hrs by celltiter-glo luminescent assay Antiproliferative activity against human CESS cells incubated for 72 hrs by celltiter-glo luminescent assay	[PMID: 39178382]
HT-29	IC₅₀	0.02 μM Compound: NVP-2; 5	Antiproliferative activity against human HT-29 cells incubated for 72 hrs by celltiter-glo luminescent assay Antiproliferative activity against human HT-29 cells incubated for 72 hrs by celltiter-glo luminescent assay	[PMID: 39178382]
Jurkat	GI₅₀	<0.16 μM Compound: NVP-2	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK8 assay Antiproliferative activity against human Jurkat cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK8 assay	[PMID: 32129996]
KG-1	IC₅₀	0.02 μM Compound: NVP-2; 5	Antiproliferative activity against human KG-1 cells incubated for 72 hrs by celltiter-glo luminescent assay Antiproliferative activity against human KG-1 cells incubated for 72 hrs by celltiter-glo luminescent assay	[PMID: 39178382]
L02	GI₅₀	28.33 μM Compound: NVP-2	Cytotoxicity against human L02 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK8 assay Cytotoxicity against human L02 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK8 assay	[PMID: 32129996]
MCF7	GI₅₀	43.36 μM Compound: NVP-2	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK8 assay	[PMID: 32129996]
MDA-MB-231	GI₅₀	<0.16 μM Compound: NVP-2	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK8 assay	[PMID: 32129996]
MV4-11	IC₅₀	0.003 μM Compound: NVP-2; 5	Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by celltiter-glo luminescent assay Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by celltiter-glo luminescent assay	[PMID: 39178382]
PC-9	IC₅₀	0.03 μM Compound: NVP-2; 5	Antiproliferative activity against human PC-9 cells incubated for 72 hrs by celltiter-glo luminescent assay Antiproliferative activity against human PC-9 cells incubated for 72 hrs by celltiter-glo luminescent assay	[PMID: 39178382]
Rec1	IC₅₀	0.03 μM Compound: NVP-2; 5	Antiproliferative activity against human REC1 cells incubated for 72 hrs by celltiter-glo luminescent assay Antiproliferative activity against human REC1 cells incubated for 72 hrs by celltiter-glo luminescent assay	[PMID: 39178382]
Sf9	IC₅₀	>10 μM Compound: NVP-2	Inhibition of recombinant human full-length N-terminal His-tagged CDK6/cyclinD3 expressed in baculovirus infected Sf9 insect cells using histone H1 as substrate measured after 60 mins by ADP-glo assay Inhibition of recombinant human full-length N-terminal His-tagged CDK6/cyclinD3 expressed in baculovirus infected Sf9 insect cells using histone H1 as substrate measured after 60 mins by ADP-glo assay	[PMID: 32129996]
Sf9	IC₅₀	0.002 μM Compound: NVP-2	Inhibition of recombinant human full-length N-terminal GST-tagged CDK9/cyclinK expressed in baculovirus infected Sf9 insect cells using PDKtide as substrate measured after 120 mins by ADP-glo assay Inhibition of recombinant human full-length N-terminal GST-tagged CDK9/cyclinK expressed in baculovirus infected Sf9 insect cells using PDKtide as substrate measured after 120 mins by ADP-glo assay	[PMID: 32129996]
Sf9	IC₅₀	3.46 μM Compound: NVP-2	Inhibition of recombinant human full-length N-terminal GST-tagged CDK2/cyclinA2 expressed in baculovirus infected Sf9 insect cells using histone H1 as substrate measured after 10 mins by ADP-glo assay Inhibition of recombinant human full-length N-terminal GST-tagged CDK2/cyclinA2 expressed in baculovirus infected Sf9 insect cells using histone H1 as substrate measured after 10 mins by ADP-glo assay	[PMID: 32129996]

In Vitro

NVP-2 has an anti-proliferation of leukemia cells, inhibits KOPT-K1, Jurkat, P12-ICHIKAWA, DU.528, MOLT 16, HSB-2, PF-382, SKW-3, SUP-T11, DND-41 and HPB-ALL cells with IC₅₀ values of 0.1688 μM, 0.1233 μM,0.5736 μM,0.1575 μM, 0.1620 μM,0.1585 μM, 0.1808 μM, 0.2589 μM, 0.0918 μM and 0.3023 μM, respectively^[1].
NVP-2 (250 nM-1 μM; 6 hours) engages CDK9 in wildtype and CRBN^/ MOLT4 cells at all concentrations, while CDK2 and CDK7 are unaffected^[1].
NVP-2 (0-10 nM; 72 hours) exhibits CRBN-dependent anti-proliferative and pro-apoptotic effects in MOLT4 cells, displays an IC₅₀ value of 9 nM^[1].
NVP-2 (250 nM; 24 hours) induces cell apoptosis in MOLT4 cells, upregulates caspase-3 and γH2A.X expression. However, while the compound washout significantly reduces the degree of apoptosis induced by NVP-2^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Leukemia cell lines
Concentration:

0.1233 µM-0.5736 µM
Incubation Time:

72 hours
Result:

Inhibited Leukemia cell lines viabity.

Western Blot Analysis^[1]

Cell Line:

Wildtype and CRBN^−/− MOLT4 cells
Concentration:

1 μM; 500 nM; 250 nM
Incubation Time:

6 hours
Result:

Degrade CDK9 sub-stoichiometrically at all concentrations.

Apoptosis Analysis^[1]

Cell Line:

Wildtype and CRBN^−/− MOLT4 cells
Concentration:

250 nM
Incubation Time:

24 hours
Result:

Induced cell apoptosis in cells and wash outed the compound relieved NVP-2-induced cell apoptosis.

Cell Proliferation Assay^[1]

Cell Line:

MOLT4 cells
Concentration:

0-10 nM
Incubation Time:

72 hours
Result:

Exhibited anti-proliferative effects in MOLT4 cells.

Chemical Information

CAS. Nr. 1263373-43-8
Appearance Solid
Molecular Weight 513.07
Formel C₂₇H₃₇ClN₆O₂
Color White to yellow
SMILES

ClC1=CN=C(N[C@H]2CC[C@H](N[C@H](C)COC)CC2)C=C1C3=CC=CC(NCC4(C#N)CCOCC4)=N3
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (41)

All WB

Sort by:

Journal Impact Factor

Nature

Inhibitors supercharge kinase turnover through native proteolytic circuits. [Abstract]

2026 Jan;649(8098):1032-1041. PMID: 41299171
Nature

Rapid unleashing of macrophage efferocytic capacity via transcriptional pause release. [Abstract]

2024 Apr;628(8007):408-415. PMID: 38480883
Cancer Cell

BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. [Abstract]

2019 May 13;35(5):752-766.e9. PMID: 31085176
Cell

Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. [Abstract]

2018 Sep 20;175(1):171-185.e25. PMID: 30146162

NVP-2 purchased from MedChemExpress. Usage Cited in: Cell. 2018 Sep 20;175(1):171-185.e25. [Abstract]

WB analysis of MV4-11 cells treated with BTX161 (6 hr), iCDK9 (4 hr), or THZ1 (4 hr) at the indicated concentrations in different combinations as indicated. PP2Ac is a loading control.
Mol Cell

PAF1C-mediated activation of CDK12/13 kinase activity is critical for CTD phosphorylation and transcript elongation. [Abstract]

2025 May 15;85(10):1952-1967.e8. PMID: 40315851
Mol Cell

Transcription-coupled AID deamination damage depends on ELOF1-associated RNA polymerase II. [Abstract]

2025 Apr 3;85(7):1280-1295.e9. PMID: 40049162
Cancer Res

Targeting transcriptional regulation with a CDK9 inhibitor suppresses growth of endocrine- and palbociclib-resistant ER+ breast cancers. [Abstract]

2024 Jan 2;84(1):17-25. PMID: 37801608
Mol Cell

SPT5 stabilization of promoter-proximal RNA polymerase II. [Abstract]

2021 Nov 4;81(21):4413-4424.e5. PMID: 34480849
Mol Cell

NELF Regulates a Promoter-Proximal Step Distinct from RNA Pol II Pause-Release. [Abstract]

2020 Apr 16;78(2):261-274.e5. PMID: 32155413
Cancer Res

Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7. [Abstract]

2019 Jul 1;79(13):3479-3491. PMID: 31064851
Nat Commun

Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]

2026 Feb 12;17(1):1214. PMID: 41680175
Nat Commun

Coordination of transcription-coupled repair and repair-independent release of lesion-stalled RNA polymerase II. [Abstract]

2024 Aug 17;15(1):7089. PMID: 39154022
Nat Commun

Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation. [Abstract]

2021 Nov 16;12(1):6607. PMID: 34785661
Nat Commun

A kinase-independent role for CDK8 in BCR-ABL1+ leukemia. [Abstract]

2019 Oct 18;10(1):4741. PMID: 31628323
Nucleic Acids Res

Genome-wide mapping of protein-DNA damage interaction by PADD-seq. [Abstract]

2023 Apr 11;51(6):e32. PMID: 36715337
Sci Adv

SPT5 regulates RNA polymerase II stability via Cullin 3-ARMC5 recognition. [Abstract]

2025 Jan 24;11(4):eadt5885. PMID: 39854452
J Biomed Sci

O-GlcNAc transferase couples MRE11 to transcriptionally active chromatin to suppress DNA damage. [Abstract]

2022 Feb 14;29(1):13. PMID: 35164752
Proc Natl Acad Sci U S A

Function-guided proximity mapping unveils electrophilic-metabolite sensing by proteins not present in their canonical locales. [Abstract]

2022 Feb 1;119(5):e2120687119. PMID: 35082156
Neoplasia

CDK9 Inhibition Induces a Metabolic Switch that Renders Prostate Cancer Cells Dependent on Fatty Acid Oxidation. [Abstract]

2019 Jul;21(7):713-720. PMID: 31151054

NVP-2 purchased from MedChemExpress. Usage Cited in: Neoplasia. 2019 Jul;21(7):713-720. [Abstract]

LNCaP cells were treated with DMSO or increasing dose of NVP2 for 24 hours and samples are analyzed using western blotting. Densitometry is used to evaluate the abundance of each protein.
Cell Chem Biol

Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. [Abstract]

2021 Feb 18;28(2):134-147.e14. PMID: 33086052
Cell Rep

ICP22-defined condensates mediate RNAPII deubiquitylation by UL36 and promote HSV-1 transcription. [Abstract]

2024 Oct 8;43(10):114792. PMID: 39383039
Cell Rep

Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma. [Abstract]

2021 Mar 16;34(11):108870. PMID: 33730585

NVP-2 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2021 Mar 16;34(11):108870. [Abstract]

NVP-2 treatment suppresses RNA polymerase II (RNAPII) CTD pSer2, pAKT, MYC, and MCL-1 levels and augments PARP cleavage in primary MCL patient samples (Pt0448, Pt1888) in a dose-dependent fashion.
J Med Chem

Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies. [Abstract]

2024 Sep 12;67(17):15220-15245. PMID: 39178382
J Med Chem

Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia. [Abstract]

2021 Oct 14;64(19):14647-14663. PMID: 34477384
Sci Signal

Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. [Abstract]

2019 Jul 16;12(590). pii: eaav7259. PMID: 31311847
Mol Cancer Res

Inhibition of O-GlcNAc Transferase Renders Prostate Cancer Cells Dependent on CDK9. [Abstract]

2020 Oct;18(10):1512-1521. PMID: 32611550
Cancer Biol Ther

NVP-2, in combination with Orlistat, represents a promising therapeutic strategy for acute myeloid leukemia. [Abstract]

2025 Dec;26(1):2450859. PMID: 39800696
Mol Oncol

Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-XL in multiple myeloma cell lines partially-dependent on MCL-1 and in plasma cells from patients. [Abstract]

2023 Dec;17(12):2507-2525. PMID: 37704591
J Cell Mol Med

Inactivation of CDK12 Enhances Mitochondrial Efficiency to Suppress DNA Damage. [Abstract]

2026 Apr;30(7):e71101. PMID: 41896195
iScience

CDK7 is a novel therapeutic target in fibrolamellar carcinoma. [Abstract]

2025 Nov 4;28(12):113925. PMID: 41321622
RNA Biol

Inhibition of CDK9 activity compromises global splicing in prostate cancer cells. [Abstract]

2021 Nov 12;18(sup2):722-729. PMID: 34592899
J Cancer Res Clin Oncol

Castration-resistant prostate cancer cells are dependent on the high activity of CDK7. [Abstract]

2023 Jul;149(8):5255-5263. PMID: 36401094
Biochem Biophys Res Commun

Brd4-dependent CDK9 expression induction upon sustained pharmacological inhibition of P-TEFb kinase activity. [Abstract]

2023 Sep 3:671:75-79. PMID: 37295357
bioRxiv

Identification of human RNA Polymerase II interactors at early stages of transcription. [Abstract]

2025 Oct 8:2025.10.08.681243. PMID: 41279442
bioRxiv

2025 March 19.
Patent

US20240425555A1.
University of California, Irvine

2024.
bioRxiv

Resistance of estrogen receptor function to BET bromodomain inhibition is mediated by transcriptional coactivator cooperativity. [Abstract]

2024 Jul 26:2024.07.25.605008. PMID: 39211208
bioRxiv

2024 July 08.
bioRxiv

2023 Mar 23.
Universidade de Lisboa

2021 Dec 21.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (194.91 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9491 mL

9.7453 mL

19.4905 mL

5 mM

0.3898 mL

1.9491 mL

3.8981 mL

10 mM

0.1949 mL

0.9745 mL

1.9491 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Winter GE, et al. BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment.Mol Cell. 2017 Jul 6;67(1):5-18.e19. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9491 mL	9.7453 mL	19.4905 mL	48.7263 mL
	5 mM	0.3898 mL	1.9491 mL	3.8981 mL	9.7453 mL
	10 mM	0.1949 mL	0.9745 mL	1.9491 mL	4.8726 mL
	15 mM	0.1299 mL	0.6497 mL	1.2994 mL	3.2484 mL
	20 mM	0.0975 mL	0.4873 mL	0.9745 mL	2.4363 mL
	25 mM	0.0780 mL	0.3898 mL	0.7796 mL	1.9491 mL
	30 mM	0.0650 mL	0.3248 mL	0.6497 mL	1.6242 mL
	40 mM	0.0487 mL	0.2436 mL	0.4873 mL	1.2182 mL
	50 mM	0.0390 mL	0.1949 mL	0.3898 mL	0.9745 mL
	60 mM	0.0325 mL	0.1624 mL	0.3248 mL	0.8121 mL
	80 mM	0.0244 mL	0.1218 mL	0.2436 mL	0.6091 mL
	100 mM	0.0195 mL	0.0975 mL	0.1949 mL	0.4873 mL

Keywords

NVP-2

41 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

NVP-2

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Chemical Probe Library

Anti-Breast Cancer Compound Library

Anti-Blood Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) NVP-2

Alle CDK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (41)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

NVP-2

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Chemical Probe Library

Anti-Breast Cancer Compound Library

Anti-Blood Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) NVP-2

Alle CDK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (41)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

NVP-2 Related Classifications

HY-12214A Related Classifications